The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials.
Front Immunol
; 13: 923106, 2022.
Статья
в английский
| MEDLINE | ID: covidwho-2109760
ABSTRACT
First-generation anit-SARS-CoV-2 vaccines were highly successful. They rapidly met an unforeseen emergency need, saved millions of lives, and simultaneously eased the burden on healthcare systems worldwide. The first-generation vaccines, however, focused too narrowly on antibody-based immunity as the sole marker of vaccine trial success, resulting in large knowledge gaps about waning vaccine protection, lack of vaccine robustness to viral mutation, and lack of efficacy in immunocompromised populations. Detailed reviews of first-generation vaccines, including their mode of action and geographical distribution, have been published elsewhere. Second-generation clinical trials must address these gaps by evaluating a broader range of immune markers, including those representing cell-mediated immunity, to ensure the most protective and long-lasting vaccines are brought to market.
ключевые слова
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
Clinical Trials as Topic
/
COVID-19 Vaccines
Тип исследования:
Экспериментальные исследования
/
Прогностическое исследование
/
Рандомизированные контролируемые испытания
Темы:
Вакцина
Пределы темы:
Люди
Язык:
английский
Журнал:
Front Immunol
Год:
2022
Тип:
Статья
Аффилированная страна:
Fimmu.2022.923106
Документы, близкие по теме
MEDLINE
...
LILACS
LIS